BWA
RCUS icon

Basecamp Wealth Advisors’s Arcus Biosciences RCUS Stock Holding History

Basecamp Wealth Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58
Closed -$1.38K – 2136
2025
Q4 		$1.38K Buy
+58
New +$1.18K ﹤0.01% 1431

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Basecamp Wealth Advisors's RCUS Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 58 shares — an estimated $1.38K sold.

Basecamp Wealth Advisors first reported a position in RCUS in Q4 2025 and held it in 1 quarter. The position peaked at $1.38K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Basecamp Wealth Advisors reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 58 Arcus Biosciences shares in Q1 2026, an estimated $1.38K.
  • Basecamp Wealth Advisors first reported a position in Arcus Biosciences in Q4 2025 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Arcus Biosciences position peaked at $1.38K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.